Pneumococcal Vaccines: Global Drug Forecast and Market Analysis to 2028
Summary
Streptococcus pneumoniae (S. pneumoniae), a Gram-positive bacterial respiratory pathogen, is a leading cause of mortality and morbidity globally and is responsible for a large proportion of deaths due to infectious disease. In 2005, The World Health Organization (WHO) estimated 1.6 million deaths were caused by S. pneumoniae annually, including 0.7-1 million children under the age of 5 years. In Europe and the US, the annual incidence of pneumococcal disease ranges from 10 to 100 per 100,000 population. S. pneumoniae causes non-invasive infections such as acute otitis media, sinusitis, and bronchitis, as well as invasive infections such as pneumonia, meningitis, and septicemia. However, the introduction of pneumococcal conjugate and polysaccharide vaccines has significantly reduced burden associated with this disease, particularly in the pediatric and elderly segments.
While the pneumococcal vaccine market has been dominated by a very small number of players in most markets (Pfizer and Merck), and relatively little unmet need remains, the size of the market makes it a compelling proposition for players to consider entering. In 2018,the publisher estimates the pneumococcal vaccines market to be $5.1B, with the best-selling vaccine globally, Prevnar (Prevenar outside the US) 13 accounting for $4.3B of these sales. Thus, while experts indicate that unmet need is modest, significant financial incentive remains for potential entrants. While the publisher anticipates new pneumococcal vaccines to be launched in the forecast period, these agents only improve upon existing options, and will not change vaccination rates or vaccination recommendations, leaving pricing increases and population growth as the major influencers of the forecast.
Key Highlights
Key Questions Answered
Scope
Reasons to Buy
The report will enable you to -
Summary
Streptococcus pneumoniae (S. pneumoniae), a Gram-positive bacterial respiratory pathogen, is a leading cause of mortality and morbidity globally and is responsible for a large proportion of deaths due to infectious disease. In 2005, The World Health Organization (WHO) estimated 1.6 million deaths were caused by S. pneumoniae annually, including 0.7-1 million children under the age of 5 years. In Europe and the US, the annual incidence of pneumococcal disease ranges from 10 to 100 per 100,000 population. S. pneumoniae causes non-invasive infections such as acute otitis media, sinusitis, and bronchitis, as well as invasive infections such as pneumonia, meningitis, and septicemia. However, the introduction of pneumococcal conjugate and polysaccharide vaccines has significantly reduced burden associated with this disease, particularly in the pediatric and elderly segments.
While the pneumococcal vaccine market has been dominated by a very small number of players in most markets (Pfizer and Merck), and relatively little unmet need remains, the size of the market makes it a compelling proposition for players to consider entering. In 2018,the publisher estimates the pneumococcal vaccines market to be $5.1B, with the best-selling vaccine globally, Prevnar (Prevenar outside the US) 13 accounting for $4.3B of these sales. Thus, while experts indicate that unmet need is modest, significant financial incentive remains for potential entrants. While the publisher anticipates new pneumococcal vaccines to be launched in the forecast period, these agents only improve upon existing options, and will not change vaccination rates or vaccination recommendations, leaving pricing increases and population growth as the major influencers of the forecast.
Key Highlights
- During the 10-year forecast period, three pipeline products that are on track to launch, driving a forecast growth in the 9MM from $5.1b in 2018 to $6.2b in 2028, which represents a CAGR of 2%.
- The late stage pipeline for pneumococcal vaccines, targeting the unmet need of serogroup coverage, includes Merck’s 15-valent pneumococcal vaccine V-114 and Pfizer’s 20-valent vaccine 20vPnC.
Key Questions Answered
- How will the pneumococcal vaccine market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Australia, South Korea) change from 2018–2028?
- What are the most promising late-stage pipeline products for pneumococcal vaccination?
- How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing immunization options?
- What are the remaining unmet needs in pneumococcal immunization?
- What drivers and barriers will affect pneumococcal vaccine sales in the 9MM over the forecast period?
Scope
- Overview of pneumococcal disease, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline pneumococcal vaccines market revenue from 2018–2028. Annual cost of immunization and major pipeline product sales in this forecast period are included.
- Key topics covered include current vaccination options, unmet needs and opportunities, and the drivers and barriers affecting pneumococcal vaccine sales in the 9MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global pneumococcal vaccine market. Insightful review of the key industry drivers, constraints, and challenges.
- Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global pneumococcal vaccine market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the pneumococcal vaccine market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Table of Contents
2 Pneumococcal Vaccines: Executive Summary
3 Introduction
4 Disease Overview
7 Competitive Assessment
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merck
- Pfizer
- SK Chemicals
